StreetInsider.com News Articles

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

Wed, 02 Sep 2026 16:10:00 -0400

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that its management team rang Nasdaq bell at the Nasdaq MarketSite in Times Square, New York, to celebrate its first quarter as a publicly traded company.

The ceremony marked the Company’s first appearance at Nasdaq since completing its business combination with Horizon Space Acquisition II Corp. and commencing trading under the ticker symbol “SLBT” on June 15, 2026. It also closes out

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

Wed, 02 Sep 2026 16:10:00 -0400

SL Science licensor files FDA drug master file for GDT exosomes

Thu, 27 Aug 2026 08:03:15 -0400

SL Science Holding Limited (NASDAQ: SLBT) announced that JY BioMed Co., Ltd., its licensor and the intellectual property holder of the Gamma Delta T (GDT) platform, has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration under number 044612, covering exosomes derived from GDT cells.

The filing adds to an existing DMF for GDT cells themselves, placing chemistry, manufacturing, and controls documentation on file with the FDA for both the cells and the cell-free exosomes those cells produce. A DMF does not constitute FDA approval of any product; it provides the agency with confidential manufacturing and quality

SL Science licensor files FDA drug master file for GDT exosomes

Thu, 27 Aug 2026 08:03:15 -0400

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

Thu, 27 Aug 2026 08:00:00 -0400

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co., Ltd. (“JY BioMed”), the intellectual property holder of the GDT platform and SL Science’s licensor.

This filing marks a significant milestone, as it extends

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

Thu, 27 Aug 2026 08:00:00 -0400

This filing marks a significant milestone, as it extends

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

Tue, 11 Aug 2026 08:00:00 -0400

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the publication of a peer-reviewed article in Biomedicines. Co-authored by SL Science leadership and clinical researchers from Taipei Medical University, the article outlines a rigorous development framework for γδ T cell therapy in glioblastoma –a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required to rigorously evaluate

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

Tue, 11 Aug 2026 08:00:00 -0400

SL Science Holding (SLBT) files for 1.04M share offering by selling stockholders

Fri, 31 Jul 2026 16:05:26 -0400

SL Science Holding (NASDAQ: SLBT) filed for up to 1,040,000 share offering by selling stockholders.

SL Science Holding (SLBT) files for 1.04M share offering by selling stockholders

Fri, 31 Jul 2026 16:05:26 -0400

SL Science Holding (NASDAQ: SLBT) filed for up to 1,040,000 share offering by selling stockholders.

SL Science presents glioblastoma cell therapy data at WCP 2026

Fri, 17 Jul 2026 08:03:21 -0400

SL Science Holding Limited (NASDAQ: SLBT) presented preclinical research on a gamma delta (γδ) T-cell therapy for glioblastoma at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026), held July 12–17 in Melbourne, Australia, according to a company statement.

The research was conducted in collaboration with Taipei Medical University, JY Biomedical Co., Ltd., and HeXun Biosciences Co., Ltd. The study examined the use of expanded γδ T cells administered directly to tumor sites in preclinical models.

Key findings from the preclinical data included complete tumor elimination by day 26 post-treatment at the highest tested dose, which used an 8:1 ratio

SL Science presents glioblastoma cell therapy data at WCP 2026

Fri, 17 Jul 2026 08:03:21 -0400

Key findings from the preclinical data included complete tumor elimination by day 26 post-treatment at the highest tested dose, which used an 8:1 ratio

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Fri, 17 Jul 2026 08:00:00 -0400

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.

TAIPEI, TAIWAN, July 17, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, today announced its successful exhibition and participation at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026) held at July 12-17, 2026 in Melbourne, Australia. Together with its esteemed academic and industry partners, the Company presented highly promising preclinical research

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Fri, 17 Jul 2026 08:00:00 -0400

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.

Form 6-K SL Science Holding Ltd For: Jul 10

Fri, 10 Jul 2026 08:56:00 -0400

si-local-file:///var/storage/secattach/20260710/26755539.html

SL Science files FDA orphan drug request for GDT glioblastoma therapy

Fri, 10 Jul 2026 08:01:13 -0400

SL Science Holding Limited (Nasdaq: SLBT), a Taiwan-based biomedical company, has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration for its Gamma Delta T cell therapy product, Vdelta2+ Gamma Delta T Cells, targeting glioblastoma multiforme (GBM).

The FDA's Office of Orphan Products Development acknowledged receipt of the request, assigned designation request number DRU-2026-11528, and is proceeding with review. The request was received March 30, 2026, and was submitted under Section 526 of the Federal Food, Drug, and Cosmetic Act.

The ODD program applies to therapies targeting diseases affecting fewer than 200,000 patients annually in the United

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Fri, 10 Jul 2026 08:00:00 -0400

Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA's Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Fri, 10 Jul 2026 08:00:00 -0400

SL Science Holding Limited Reports Full Year 2025 Financial Results

Thu, 18 Jun 2026 17:13:00 -0400

Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced its financial results for the full year ended December 31, 2025.

Management Commentary

"2025 was a highly transformative and foundational year for SL Science as we aggressively advanced our core cell therapy pipeline and executed our long-term strategic shift toward next-generation immunotherapies. Throughout the past year, we strategically prioritized our resources on high-value clinical research and development, committing over $2.07 million to expand

SL Science Holding Limited Reports Full Year 2025 Financial Results

Thu, 18 Jun 2026 17:13:00 -0400

Management Commentary

Form SCHEDULE 13D SL Science Holding Ltd Filed by: Wang Ching-Dong

Thu, 18 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260618/26666748.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Wang Ching-Dong

Thu, 18 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260618/26666742.html

Form 20-F SL Science Holding Ltd For: Jun 12

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666586.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: Xu Qian

Wed, 17 Jun 2026 11:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26658457.html

Form 3 SL Science Holding Ltd For: Jun 12 Filed by: LAU JOHNSON SHUN-PONG

Tue, 16 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260616/26655289.html